Show results for
  • Sygnature
  • News
  • Drug Discovery
  • Therapeutic Areas
  • Events
  • Vacancies

Hit Identification to 3 Compounds in the Clinic and 6 Development Candidates

  • UK-based small molecule drug discovery company
  • Focus on identifying novel treatments of inflammatory respiratory diseases, such as COPD
  • No in-house medicinal chemistry capability – Sygnature has been the company’s exclusive
    medicinal chemistry team since 2007, providing multiple FTEs of resource + intellectual input
  • Considerable intellectual input from Sygnature’s chemists – named on more than 20 patents and patent applications (so far)
  • 3 Compounds discovered at Sygnature have entered the clinic (Phases I and IIa) as potential ‘first-in-class’ treatments, and 6 more compounds have entered pre-clinical development
  • The company was acquired by a major multi-national pharmaceutical company in 2010
  • Since the acquisition, Sygnature has enjoyed a large FTE-based collaboration (medicinal
    chemistry and in vitro bioscience) to discover additional small molecule-based drug candidates

Get in Touch

For more details on how we can provide innovative support to your project please use this contact form.

CTA Form

The information you supply will be processed in accordance with the General Data Protection Regulation (EU) 2016/679. For further details about how Sygnature Discovery collects, uses and stores personal data, please refer to our Website Privacy Notice available here.